Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Revue Francaise d'Allergologie ; 62(3):317-318, 2022.
Article in French | EMBASE | ID: covidwho-2004467

ABSTRACT

Déclaration de liens d’intérêts: Les auteurs n’ont pas précisé leurs éventuels liens d’intérêts.

2.
Revue Française d'Allergologie ; 61(4):292-293, 2021.
Article in French | PMC | ID: covidwho-1225383
3.
Respir Med Res ; 79: 100801, 2021 May.
Article in English | MEDLINE | ID: covidwho-1065556

ABSTRACT

BACKGROUND: Scant data are currently available about a potential link between comorbid chronic lung diseases (CLD) and the risk and severity of the coronavirus disease 2019 (COVID-19) infection. METHODS: To describe the clinical characteristics of and outcomes for patients with COVID-19 infection, including patients with comorbid respiratory diseases, who have been primarily hospitalized in the pulmonology department of Strasbourg University Hospital, France. In this retrospective, single-center study, we included all confirmed cases of COVID-19 from March 3 to April 15, 2020. We then compared the symptoms, biological and radiological findings, and outcomes for patients with and without CLD. RESULTS: Of the 124 patients that were enrolled, the median age was 62 years, and 75 patients (60%) were male. Overall, 40% of patients (n=50) had preexisting CLD, including chronic obstructive pulmonary disease (COPD) (n=15, 12%) and asthma (n=19, 15%). Twenty-eight patients were transferred to the intensive care unit (ICU), and six patients died in our unit. CLD were not predictive of ICU hospitalization, but a significantly higher total mortality was observed (17.6% vs. 5.5%, P<0.05) in these patients. CONCLUSIONS: Our results suggest the lack of an over-representation of CLD in COVID-19, representing 40% of patients in this cohort and even within a pulmonology department. CLD were not a risk factor for ICU management. However, a tendency to higher global mortality was observed in COVID-19 patients with CLD. Further studies are warranted to determine the risk of COVID-19 for patients with comorbid CLD.


Subject(s)
COVID-19/therapy , Chronic Disease/therapy , Lung Diseases/therapy , Aged , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/epidemiology , Chronic Disease/epidemiology , Comorbidity , Continuous Positive Airway Pressure , Diabetes Mellitus/epidemiology , Female , France/epidemiology , Heart Failure/epidemiology , Hospital Mortality , Hospitalization , Hospitals, University , Humans , Hydroxychloroquine/therapeutic use , Hypertension/epidemiology , Intensive Care Units , Lung Diseases/epidemiology , Male , Middle Aged , Noninvasive Ventilation , Obesity/epidemiology , Oxygen Inhalation Therapy , Retrospective Studies , Sleep Apnea Syndromes/epidemiology , Smoking/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL